UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549



FORM 10-Q/A

Amendment No. 1



| | ☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| | - | ---------------------------------------------------------------------------------------



For the quarterly period ended September
30, 2019





| | ☐ | TRANSITION REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
| | - | ----------------------------------------------------------------------------------------



For the transition period from ___ to ___



Commission file number: 000-30991



SKINOVATION PHARMACEUTICAL INCORPORATED

(Exact name
of registrant as specified in its charter)

|Wyoming
        (State or other jurisdiction of incorporation or organization)                | 87-0458170
        (I.R.S. Employer Identification No.)
|--------------------------------------------------------------------------------------------- | -------------------------------------------------------
|2157 S. Lincoln Street, Salt Lake City, Utah
        (Address of principal executive offices) | 84106
        (Zip Code)                               

(801) 323-2395

(Registrant’s telephone number, including
area code)



Securities registered pursuant to Section 12(b) of the Act:



|Title of each class | Trading Symbol(s) | Name of each exchange on which registered
|------------------- | ----------------- | -----------------------------------------
|None                |                   |                                          



Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. Yes ☑ No ☐



Indicate by check mark whether the registrant has submitted electronically
every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during
the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐



Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging
growth company” in Rule 12b-2 of the Exchange Act.



|Large accelerated filer ☐
        
        Non-accelerated filer ☑ | Accelerated filer ☐
        Smaller reporting company ☑
        Emerging growth company ☑
|------------------------------------------------------------------ | -----------------------------------------------------------------------------------------



If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐



Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act). Yes ☑ No ☐



The number of shares outstanding of the registrant’s common
stock as of November 12, 2019 was 708,000.









EXPLANATORY NOTE



This amendment to the Company’s report on Form 10-Q for the
period ended September 30, 2019, filed November 12, 2019, is being filed to correct the financial number disclosures included in
the “Results of Operations” in “Item 2. Management’s Discussion and Analysis of Financial Condition and
Results of Operations.”



We are filing this amendment and re-executed Section 305 and Section
906 certifications required by the Sarbanes-Oxley Act of 2002. Please note that this Form 10-Q does not include subsequent events
occurring after the original filing date of the Form 10-Q.





PART I – FINANCIAL INFORMATION



ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS



Executive Overview



We have not recorded revenues and we are dependent upon financing
to continue basic operations. Management intends to rely upon advances or loans from management, significant stockholders or third
parties to meet our cash requirements, but we have not entered into written agreements guaranteeing funds and, therefore, no one
is obligated to provide funds to us in the future. These factors raise substantial doubt as to our ability to continue as a going
concern. Our plan is to combine with an operating company to generate revenue.



As of the date of this report, our management has not had any discussions
with any representative of any other entity regarding a business combination with us. Any target business that is selected may
be a financially unstable company or an entity in its early stages of development or growth, including entities without established
records of sales or earnings. In that event, we will be subject to numerous risks inherent in the business and operations of financially
unstable and early stage or potential emerging growth companies. In addition, we may effect a business combination with an entity
in an industry characterized by a high level of risk, and, although our management will endeavor to evaluate the risks inherent
in a particular target business, there can be no assurance that we will properly ascertain or assess all significant risks. In
addition, any business combination or transaction will likely result in a significant issuance of shares and substantial dilution
to present stockholders of the Company.



We anticipate that the selection of a business opportunity will
be complex and extremely risky. Because of general economic conditions, rapid technological advances being made in some industries
and shortages of available capital, our management believes that there are numerous firms seeking the perceived benefits of becoming
a publicly traded corporation. Such perceived benefits of becoming a publicly traded corporation include, among other things, facilitating
or improving the terms on which additional equity financing may be obtained, providing liquidity for the principals of and investors
in a business, creating a means for providing incentive stock options or similar benefits to key employees, and offering greater
flexibility in structuring acquisitions, joint ventures and the like through the issuance of securities. Potentially available
business combinations may occur in many different industries and at various stages of development, all of which will make the task
of comparative investigation and analysis of such business opportunities extremely difficult and complex.



If we obtain a business opportunity, then it may be necessary to
raise additional capital. We anticipate that we will sell our common stock to raise this additional capital. We expect that we
would issue such stock pursuant to exemptions to the registration requirements provided by federal and state securities laws. The
purchasers and manner of issuance will be determined according to our financial needs and the available exemptions to the registration
requirements of the Securities Act of 1933. We do not currently intend to make a public offering of our stock. We also note that
if we issue more shares of our common stock, then our stockholders may experience dilution in the value per share of their common
stock.



Liquidity and Capital Resources



We have not recorded revenues from operations during 2019 and 2018
and have not established an ongoing source of revenue sufficient to cover our operating costs. We expect to rely upon third parties
to pay for our operating expenses. At September 30, 2019 we had cash of $92 compared to $132 cash at December 31, 2018. Our total
liabilities increased to $307,448 at September 30, 2019 from $284,590 at December 31, 2018. The increase in total liabilities is
primarily due to increases in accounts payable for professional fees, notes payable and accrued interest.



We intend to obtain capital from management, significant stockholders
and third parties to cover minimal operations; however, there is no assurance that additional funding will be available. Our ability
to continue as a going concern during the long term is dependent upon our ability to find a suitable business opportunity and acquire
or enter into a merger with such company. The type of business opportunity with which we acquire or merge will affect our profitability
for the long term.



During the next 12 months we anticipate incurring additional costs
related to the filing of Exchange Act reports. We believe we will be able to meet these costs through advances and loans provided
by management, significant stockholders or third parties. We may also rely on the issuance of our common stock in lieu of cash
to convert debt or pay for expenses.



Results of Operations



We did not record revenues in either 2019 or 2018. General and administrative
expense was $10,840 for the nine months ended September 30, 2019 (“2019 nine month period”) compared to $10,800 for
the nine months ended September 30, 2018 (“2018 nine month period”). General and administrative expense was $2,715
for the three months ended September 30, 2019 (“2019 third quarter”) compared to $2,615 for the three months ended
September 30, 2018 (“2018 third quarter”).



Total other expense increased to $12,058 for the 2019 nine month
period compared to $11,338 for the 2018 nine month period. Total other expense increased to $4,085 for the 2019 third quarter compared
to $3,812 for the 2018 third quarter. Total other expense represents interest expense related to notes payable.



Our net loss increased to $22,898 for the 2019 nine month period
compared to $22,138 for the 2018 nine month period. Our net loss increased to $6,800 for the 2019 third quarter compared to $6,427
for the 2018 third quarter. Management expects net losses to continue until we acquire or merge with a business opportunity.



Commitments and Obligations



At September 30, 2019 we had outstanding notes payable totaling
$205,721. During the 2019 nine month period a third party loaned the Company $7,400. All of the notes payable are non-collateralized,
carry interest at 8% and are due on demand. For the 2019 nine month period we recorded interest expense of $12,058 for notes payable
and recorded total accrued interest at September 30, 2019 of $90,627.



During the 2019 nine month period we incurred $3,400 in accounts
payable for consulting services and professional services provided or paid for by third parties. Total accounts payable at September
30, 2019 were $11,100.



Two lenders represent in excess of 95% of the Company’s accounts
payable and notes payable at September 30, 2019.



Off-Balance Sheet Arrangements



We have not entered into any off-balance sheet arrangements that
have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues
or expenses, results of operations, liquidity, capital expenditures or capital resources and would be considered material to investors.



Emerging Growth Company



We qualify as an emerging growth company as that term is used in
the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). A company qualifies as an emerging growth company
if it has total annual gross revenues of less than $1.07 billion during its most recently completed fiscal year and, as of December
8, 2011, had not sold common equity securities under a registration statement. Under the JOBS Act we are permitted to, and intend
to, rely on exemptions from certain disclosure requirements



In addition, Section 107 of the JOBS Act also provides that an emerging
growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying
with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting
standards until those standards would otherwise apply to private companies. We have elected to take advantage of the benefits of
this extended transition period. Our financial statements may therefore not be comparable to those of companies that comply with
such new or revised accounting standards.





PART II – OTHER INFORMATION



ITEM 6. EXHIBITS



Part I Exhibits

|No.  | Description                              
|---- | -----------------------------------------
|31.1 | Principal Executive Officer Certification
|31.2 | Principal Financial Officer Certification
|32.1 | Section 1350 Certification               





Part II Exhibits

|No.     | Description                                                                                                                                
|------- | -------------------------------------------------------------------------------------------------------------------------------------------
|3(i)    | Wyoming Articles of Domestication, filed November 23, 2016
(Incorporated by reference to exhibit 3(i).2 of Form 10-K, filed March 20, 2017)
|3(ii)   | Bylaws of Skinovation (Incorporated by reference to exhibit
3(ii) of Form 10-K, filed March 20, 2017)                                      
|101.INS | XBRL Instance Document  (Filed November 12, 2019)                                                                                          
|101.SCH | XBRL Taxonomy Extension Schema Document (Filed November 12, 2019)                                                                          
|101.CAL | XBRL Taxonomy Calculation Linkbase Document (Filed November 12, 2019)                                                                      
|101.DEF | XBRL Taxonomy Extension Definition Linkbase Document (Filed November 12, 2019)                                                             
|101.LAB | XBRL Taxonomy Label Linkbase Document (Filed November 12, 2019)                                                                            
|101.PRE | XBRL Taxonomy Presentation Linkbase Document (Filed November 12, 2019)                                                                     













SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



|Date: November 15, 2019 | SKINOVATION PHARMACEUTICAL INCORPORATED
        
        
        By:   /s/ Hugo Rodier
        Hugo Rodier
        President and Director
        Principal Financial Officer
|----------------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------